ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced lung cancer: drug cocktails under trial
Disease control Recruiting nowThis study tests new combinations of cancer drugs in people with advanced or metastatic non-small cell lung cancer. The goal is to find safer and more effective treatments. About 152 participants will receive either novel drug pairs or new drugs plus standard therapy. The study f…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat lung tumors
Disease control Recruiting nowThis study tests a new drug called SHR-A2102 combined with the immunotherapy adebrelimab, with or without chemotherapy or bevacizumab, in 248 people with advanced or metastatic non-small cell lung cancer. The goal is to find the safest dose and see if the combination can shrink t…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New lung cancer cocktail aims to outperform current standard
Disease control Recruiting nowThis Phase 3 trial tests whether adding a new drug (SHR-8068) to a standard immunotherapy (adebrelimab) and chemotherapy works better than the current standard (tislelizumab plus chemo) for people with advanced non-small cell lung cancer. About 460 participants will be randomly a…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC